An analysis on treatment effect of blue light phototherapy combined with Bifico in treating neonatal hemolytic jaundice

Abstract

This study aimed to discuss and evaluate the clinical effect of blue light phototherapy combined with bifico in treating neonatal hemolytic jaundice. One hundred and twenty cases with neonatal hemolytic jaundice were randomly divided into treatment group and control group, 60 cases in each group. Neonatal patients in the control group were treated with traditional treatment, including administration of enzyme inducer phenobarbital and blue light phototherapy for 8 consecutive hours every day. Neonatal patients in the treatment group received bifico orally based on traditional treatment. Clinical effects of the two groups were observed after one course of treatment (7 days as one course). During the first course, serum bilirubin level in the treatment group treated with blue light phototherapy combined with bifico declined more rapidly (P<0.01) and more significantly (P<0.01) than that in the control group, and the mean time for eliminating jaundice was significantly reduced (P<0.05). The total effective rate was 91.67% in the treatment group, while that was 85.00% in the control group, which suggested that the treatment effect of the treatment group was better than that of the control group and the difference between the two groups was statistically significant (P<0.05). Compared with traditional treatment, the treatment effect of blue light phototherapy combined with bifico in treating neonatal hemolytic jaundice is significantly improved and the speed of eliminating jaundice is also higher. Thus, it is worthy to be applied in clinical practice.

Analysis of therapeutic effect of intermittent and continuous phototherapy on neonatal hemolytic jaundice

“…Also ABO-incompatibility is the most common cause of hemolytic disease in newborns, occuring commonly in maternal type O blood and type A or B blood in newborns as well as in the ABO hemolytic jaundice (16,17). ABO hemolytic jaundice is a serious pathological jaundice, which can cause neonatal growth and development disorders and irreversible effects on the nervous system if patients receive inappropriate or not well-timed treatment (18). Some documents have shown that phototherapy irradiation can make bilirubin from the serum of children absorb certain wavelength of light, resulting in the transformation of its structure and properties.…”

Challenges of phototherapy for neonatal hyperbilirubinemia (Review)

“…Although there are several treatment schemes available in the clinical setting, blue light is generally the preferred choice for preventing the development of bilirubin encephalopathy or nuclear jaundice caused by excessive accumulation of unconjugated bilirubin ( 6 , 7 ). A high serum level of free bilirubin may cause neurotoxicity, but mildly elevated bilirubin concentrations are beneficial due to their protective antioxidant role in cell membranes, while markedly low concentrations may also be harmful ( 8 , 9 ).…”

Chinese expert consensus on the application of live combined Bifidobacterium, Lactobacillus, and Enterococcus powder/capsule in digestive system diseases (2021)

“…Agreement: 92.31%. Numerous studies showed that the combination of Bifidobacterium triple viable powder/capsule with conventional treatment showed definite efficacy in neonatal jaundice, [48][49][50] improved the overall efficiency, and effectively reduced the number of days of jaundice duration in children and accelerated the resolution of jaundice. 51 The recommended dosage is 0.5 g per dose, three times per day.…”